Navigation Links
Investigational drug effective in treating iron deficiency in kidney disease patients on dialysis
Date:11/9/2013

ATLANTA, GA Doctors at the North Shore-LIJ Health System on Saturday will present late-breaking data showing that an investigational drug Triferic is well tolerated and effective in treating iron deficiency in patients with chronic kidney disease undergoing dialysis. This data will be presented at the American Society of Nephrology's Kidney Week 2013 in Atlanta, GA.

Chronic kidney disease (CKD) is the slow loss of kidney function over time. The main function of the kidneys is to remove wastes and excess water from the body. When chronic kidney failure reaches an advanced stage, dangerous levels of fluid, electrolytes and wastes can accumulate in the body, and a patient will need to undergo hemodialysis (dialysis) a machine that filters wastes, salts and fluid from the blood. A common problem for patients on dialysis is iron deficiency. The body needs a certain amount of iron for overall good health and healthy blood cells, but excess iron gradually builds up in tissues and organs, eventually damaging them. Standard, current care for dialysis patients with iron deficiency is to intravenously inject 100 mg of iron into the bloodstream. But this method can result in oxidative stress and harm to people on dialysis.

Steven Fishbane, MD, and Azzour Hazzan, MD from the North Shore-LIJ Health System's Division of Nephrology in New York, in collaboration with Ajay Singh, MD, associate professor at Harvard Medical School, conducted two Phase 3 trials, CRUISE-1 and CRUISE-2, which demonstrated, in 300 patients in each trial, that Triferic administered at each dialysis treatment for up to 48 weeks effectively delivers iron and maintains the body's hemoglobin concentration constant. Triferic is a novel iron compound that has a unique mode of action in that it is delivered to the patient via their dialysis treatment as opposed to intravenous delivery. Triferic gradually delivers iron to the bone marrow and maintains hemoglobin without the rapid flux of iron caused by intravenous injection.

"Up until now, iron deficiency in chronic kidney disease patients who undergo dialysis has been treated almost exclusively with intravenous iron, which injects a large amount of iron directly into the blood stream. This can potentially be toxic for patients," said Dr. Fishbane. "Our study is important and should be of interest to patients because it shows Triferic is effective in preventing iron deficiency without inducing iron overload in patients. It more closely mimics the slower natural way of absorbing iron and with additional studies, we might be able to show it is an improved and preferred treatment option."


'/>"/>

Contact: Emily Eng
eng3@nshs.edu
516-562-2670
North Shore-Long Island Jewish (LIJ) Health System
Source:Eurekalert

Related medicine news :

1. Investigational agent targets gene signaling pathways to improve response for patients with CLL
2. Method patent issued for investigational new class of pain medication
3. Investigational malaria vaccine found safe and protective
4. Targeted investigational therapy potential to overcome crizotinib resistance in lung cancers
5. Investigational PARP inhibitor promising in BRCA-related cancers
6. NIH launches trial of investigational genital herpes vaccine
7. Investigational Drug Effective in Treating Iron Deficiency in Chronic Kidney Disease Patients on Dialysis: Study
8. HIV Prevention Pill Cost-Effective for High-Risk Men: Study
9. Pig stomach mucins are effective as anti-viral agents for consumer products
10. Lower-Dose Radioiodine Effective Against Thyroid Cancer
11. Aspirin as Effective as Warfarin for Heart Failure: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2017)... ... June 24, 2017 , ... ... Located at 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and ... so that visits to the dentist fit into their patients’ busy lifestyles. Dental365 ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... the launch of Care Management Alerts and Dashboards, an innovative new service enabling ... Island. , RIQI’s Care Management Alerts and Dashboards provide near real-time data about ...
(Date:6/23/2017)... ... 2017 , ... Yesterday, U.S. Senate Republicans revealed details of ... replace the Affordable Care Act (ACA). Like the bill narrowly passed by the ... public health insurance program for low-income children, pregnant women, parents of dependent children, ...
(Date:6/23/2017)... ... 2017 , ... Dr. Ran Y. Rubinstein , a ... offering three new minimally invasive procedures to patients who want a younger and ... Rubinstein is excited to bring microneedling, microneedling facials, and platelet rich plasma (PRP) ...
(Date:6/23/2017)... ... ... Goodcents Deli Fresh Subs today announced the opening of a new restaurant in ... Kan. 66604 (near 21st and Gage). It is owned and operated by long-time Goodcents ... the Topeka and Bonner Springs, Kan. area. , “Goodcents has such a loyal ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... Fla. , June 8, 2017  Less than ... that hit more than 200,000 companies, including hospital networks, ... being heralded as one of the largest online extortion ... in the healthcare market, it is imperative that providers ... protect their data from this — and many other ...
(Date:6/7/2017)... 2017  Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy, ... Iowa location. The ... features an ISO 7 cleanroom—the standard needed to compound intravenous (IV) ... level of pollutants. "Our new ... better serve our Iowa patients," said ...
(Date:6/1/2017)... BLUE BELL, Pa. , June 1, 2017 /PRNewswire/ ... Nutriceuticals (PRN) and Veterinarian Recommended Solutions (VRS), and KD ... direct investment in Nutriceutical Holdings by KD Pharma Group. ... Nutriceutical Holdings with the option to acquire the entire ... ideal partner in KD. They are committed to growing ...
Breaking Medicine Technology: